Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Global Pet Food Packaging Machinery Market to Reach USD 3.8 Billion by 2033, Driven by Rising Pet Ownership and Manufacturing ExpansionOpportunities center on automated, flexible machinery for smaller packs, premium and customized pet foods, and e-commerce-ready formats. Rising pet ownership and expanding production are driving demand across developed and emerging markets.
- OrderCounter and Maple Launch Strategic Partnership to Enable AI Phone Ordering Built for Hybrid POSNEW YORK & PENSACOLA, Fla., August 31, 2026--OrderCounter, the hybrid point-of-sale provider that pairs the reliability of an on-site server with the accessibility of the cloud, and Maple, the leading voice AI platform for restaurants, today announced a partnership that brings automated phone ordering to OrderCounter's restaurant customers.
- GREY GOOSEGREY GOOSE® VODKA TOASTS THE US OPEN® WITH JOSH HART, NEW YORK'S ULTIMATE BALLERThe GREY GOOSE Honey Deuce® US Open Signature Cocktail and Last Serve Bar return September 2–3 as GREY GOOSE celebrates 20 years at the US Open® — GREY GOOSE® vodka returns to the US Open® for its 20th year, continuing one of the longest...
- Kaplan Fox & Kilsheimer LLPKaplan Fox Notifies Simply Good Foods Company (SMPL) Investors of a Securities Class Action Deadline on October 13, 2026Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against The Simply Good Foods Company ("Simply Good" or the "Company") (NASDAQ: SMPL) on behalf of investors that purchased or otherwise acquired Good Foods common stock between October 24, 2024 and April 8, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Simply Good and have suffered losses, you may CLICK HERE to contact us. You...
- Galaxis Technology Announces 2026 Interim Results, Revenue Surges 45.1% YoY and Overseas Business Expansion AcceleratesThe integrated intelligent intralogistics robotics provider - Zhejiang Galaxis Technology Group Co., Ltd. (“Galaxis Technology” or the “Company”, stock code: 2729.HK) is pleased to announce its interim results for the six-month period ended 30 June 2026 (the “Reporting Period”). During the Reporting Period, the Company recorded revenue of approximately RMB504.9 million, representing a YoY increase of 45.1%. The revenue growth was mainly attributable to the increase in the number of large-scale multi-function comprehensive system and AMR deployment projects delivered in PRC. The gross profit was approximately RMB88.2 million, representing a YoY increase of 42.7% and a gross profit margin of 17.5%. The loss for the period decreased to approximately RMB73.3 million, narrowing by 14.7% YoY. As at 30 June 2026, the Company achieved an aggregate backlog value of robots and systems of approximately RMB2.2 billion, which the Company expects to fulfill within the next three years, out of which 56 were ongoing overseas projects with an aggregate backlog value of RMB710 million. During the Reporting Period, the Company has been carrying out its globalization strategy systematically in overseas markets, setting up local teams in North America, Southeast Asia, South America, Europe and other overseas markets. The total number of its overseas partners reached 22, and its business has expanded to 31 countries and regions. Business opportunities sourced from overseas markets increased substantially by 61.5%. The Company made multiple key progress in overseas markets. It entered into the Australian market with very-narrow-aisle fork-type robots (VFRs) and secured project orders for VFR from a health supplement manufacturing company; officially entered the global shuttle system supplier directory of a globally renowned Swedish home goods retailer; secured new VFR projects in Japan with a leading global electronics manufacturer and a domestic furniture retailer, which marked its market presence in Japan; secured a new pallet shuttle project with a Brazilian food processing company, making progress in the development of South American markets. In terms of domestic market development, during the Reporting Period, the Company successfully completed a core exemplary project in the Chinese Mainland. The project deployed 120 MSRs, 98 VFRs and a 15-kilometer-long automated conveyor track, with a daily outbound processing capacity of 320,000 order lines, a daily throughput of 60,000 items, and a shipping accuracy and timely delivery rate above 99.9%, which fully illustrates its strengths in technology implementation and systematic delivery in large-scale and complex projects. The Company adheres to the R&D philosophy of “scenario-oriented, technology-based”, continuously strengthening its integrated hardware and software technical edges and enriching its robot portfolio to meet the diverse needs of intralogistics scenarios. Its R&D expenses during the Reporting Period amounted to RMB38.7 million, representing a YoY increase of 27.3%. As at 30 June 2026, the Company has 965 employees in total, among whom 286 are R&D personnel, accounting for 29.6% of the total headcount. The consistent investment in R&D and talent accumulation is being translated into a core driving force for product iteration and scenario-based deployment, laying a deep and solid foundation for the Company’s long-term competitive advantages. Looking ahead, Dr. GU Chunguang, Chairman of the Board, Executive Director and Chief Executive Officer of Galaxis Technology, stated: “In the first half of 2026, we achieved substantial revenue growth, secured benchmark projects in domestic and overseas markets and narrowed loss, which reflects positive operating momentum. Going forward, we will continue to follow the long-term development path of ‘based in China, best in global’ by maintaining product innovation leadership through continued investment in R&D; strengthening localized execution in overseas markets; expanding into new industries and application scenarios; reinforcing industrial-chain collaboration; and improving management and operating efficiency, and achieve sustainable growth in both domestic and international markets. Thus, we can further strengthen our core competitive strengths.” About Zhejiang Galaxis Technology Group Co., Ltd. Galaxis Technology (Stock Code: 2729.HK) is an intelligent intralogistics robotics provider focused on advancing automation in modern warehouse operations. The Company provides robotics products centred on three core product lines: multi-directional shuttle robots (MSRs), autonomous mobile robots (AMRs), and conveying and sorting robots (CSRs). These products possess core functions of storage, sorting and transport and cover the full scope of intralogistics business operations. Through sustained investment in R&D, the Company has established a comprehensive intellectual property portfolio, including invention patents, utility models, and design patents. Over the years, it built extensive experience in delivering integrated intralogistics solutions across multiple industries. This press release is issued on behalf of Zhejiang Galaxis Technology Group Co., Ltd. by Porda Havas International Finance Communications Group. Should you have any enquiries, please contact: Porda Havas International Finance Communications Group Email: [email protected]
- AdvoCare® Launches Clear ProteinRICHARDSON, Texas, August 31, 2026--AdvoCare International, LLC, a leading health and wellness company, is pleased to announce the launch of Clear Protein, a refreshing new take on protein supplementation that delivers 20g of high‑quality protein, 0g sugar, and crisp fruit flavors — all in a light, juice‑like drink.
- Inaba Foods USA IncINABA Foods USA Announces In-Store Debut of Churu Complete 3oz Cans at TargetLatest innovation in complete cat meals will be available first at Target stores ahead of a broader national rollout — INABA Foods USA, maker of the popular Churu® lickable treats for cats and dogs, announced today that Churu Complete 3oz Cans made...
- Beyond Air™Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to LungFit GO for the treatment of nontuberculous mycobacterial pulmonary disease (NTM-PD).
- Applebee’s® Introduces NFL Season Wing Ticket: Free Boneless Wings WeeklyPASADENA, Calif., August 31, 2026--Football season is back, and Applebee’s, the Official Grill + Bar Sponsor of the NFL, has one of the hottest tickets in town for fans hunting for gameday food deals. Starting today, guests can sign up for the free Applebee’s NFL Season Wing Ticket, a season-long pass that unlocks six free Boneless Wings To Go every week with a $15 online purchase.
- Micot Pharma Reports Positive Operating Cash Flow and Advances Late-Stage Pipeline in 1H 2026Operating Cash Flow Turns Positive for the First Time, with a Significantly Strengthened Capital Structure On August 28, 2026, Micot Pharma (02335.HK), the first publicly listed peptide-focused innovative drug company in Hong Kong, announced its interim results for the first half of 2026. During the reporting period, the Company recorded research and development expenses of RMB128 million, representing a significant year-on-year increase of 215.9%, reflecting an acceleration in R&D investment. Meanwhile, net cash generated from operating activities reached RMB109 million, marking a turnaround from net operating cash outflow in the corresponding period of 2025. An important contributor to this shift was the commercialization partnership for MT1013. In February 2026, Micot Pharma entered into an exclusive commercialization licensing agreement with Everest Medicines for MT1013, the Company's Core Product. Under the agreement, Everest Medicines was granted exclusive commercialization rights for MT1013 in Greater China and the Asia-Pacific region excluding Japan for the treatment of secondary hyperparathyroidism (SHPT). Micot Pharma received an upfront payment of RMB200 million and is eligible to receive potential regulatory and commercial milestone payments of up to RMB1.04 billion, as well as tiered royalties based on net product sales. As of the end of June 2026, the Company's cash and financial assets totaled approximately RMB1.227 billion, compared with RMB270 million at the end of 2025. Total equity reached approximately RMB957 million, compared with net liabilities of approximately RMB960 million at the end of 2025. The Company's gearing ratio also declined substantially from 389.6% to 25.2%. For a clinical-stage biotechnology company, the strengthening of liquidity and capital structure provides important financial support for the continued advancement of multiple clinical programs. MT1013 Advances Through Phase III, with a Clearer Path Toward Commercialization Beyond its financial position, the key question for the market remains the progress and clinical potential of Micot Pharma's pipeline. MT1013 remains the Company's most advanced asset and the product closest to commercialization. MT1013 is the world’s first-in-class, new-generation dual-targeting peptide drug being developed for secondary hyperparathyroidism associated with chronic kidney disease (CKD-SHPT).The drug features a pioneering dual mechanism of action—“CaSR agonist + OGP (Osteogenic Growth Peptide) mimetic.” Unlike conventional approaches that primarily focus on suppressing parathyroid hormone (PTH), MT1013 is designed to regulate PTH, calcium and phosphorus metabolism while simultaneously activating osteogenic pathways to promote bone formation and repair. This represents a potential therapeutic shift from indirectly suppressing bone resorption toward actively promoting bone formation. The Phase III clinical study of MT1013 has completed patient enrollment, and the Company expects to submit a New Drug Application (NDA) in early 2027. In a head-to-head clinical study against the calcimimetic etelcalcetide, the composite target attainment rate for serum calcium, phosphorus, and iPTH in the MT1013 groups after 20–27 weeks of treatment was 39.29% and 34.48%, respectively, approximately 2.2–2.5 times that of etelcalcetide (15.63%). In addition, the proportion of patients in the MT1013 groups achieving a reduction of more than 30% in intact parathyroid hormone (iPTH) from baseline reached 83.9%–93.3%. Clinical data from MT1013 have also been accepted as Late-Breaking Science by the American Society of Nephrology (ASN) Kidney Week. Against this backdrop, Micot Pharma's commercialization partnership with Everest Medicines represents an important step in translating the clinical and scientific value of MT1013 into potential commercial value. Positive Phase II Data for MT200605 Further Validate Its Potential as an Innovative Stroke Therapy Shortly before the release of its interim results, Micot Pharma announced on August 26 that it had completed the Phase II clinical trial of MT200605, its internally developed candidate for the treatment of acute ischemic stroke (AIS). The study was a multicenter, randomized, double-blind, placebo-controlled Phase II trial involving 360 patients, who were randomized at a 1:1:1:1 ratio into three MT200605 dose groups and a placebo group. For the primary efficacy endpoint, the proportion of patients achieving a modified Rankin Scale (mRS) score of 0–1 in the high-dose MT200605 group was higher than that in the placebo group, with the odds ratio (OR) for functional recovery improving by more than 100% versus placebo. From a clinical-benefit perspective, the results suggest that approximately one additional patient could achieve functional independence for every six patients treated. The signal is noteworthy in the context of neuroprotection research, a field in which translating biological mechanisms into meaningful improvements in functional outcomes has historically been challenging. For the secondary endpoints, improvement in National Institutes of Health Stroke Scale (NIHSS) scores in the high-dose group began to separate from placebo by Day 7. The direction of improvement was consistent with the mRS results, with a more pronounced difference observed by Day 14, suggesting faster early neurological recovery among patients receiving high-dose MT200605. Another differentiated observation involved acute kidney injury (AKI). MT200605 demonstrated the potential to reduce the incidence of AKI among patients with AIS in a dose-dependent manner. In the high-dose group, the incidence of AKI was more than 80% lower than that in the placebo group, indicating potential renal-protective benefits in addition to its neurological effects. A Differentiated BDNF/TrkB-Based Mechanism Supporting Potential Brain and Kidney Protection Mechanistically, MT200605 is a small molecule compound that acts as a tropomyosin receptor kinase B (TrkB) agonist with brain-derived neurotrophic factor (BDNF)-like effects. By activating TrkB, it modulates downstream signaling pathways to protect the structure and function of brain neural tissues. Additionally, it enhances mitochondrial ATP synthesis and exerts antioxidant effects by scavenging oxygen free radicals. This differentiated mechanism may also contribute to the renal-protective signal observed in the Phase II trial. MT200605 has received recognition from both domestic and international scientific and regulatory communities. The program has been selected for China's National Science and Technology Major Project for Innovative Drug Development. Its preclinical and Phase I clinical findings have also been accepted for oral presentation at the 18th World Stroke Congress. In addition, the U.S. Food and Drug Administration granted Orphan Drug Designation to MT200605 for the treatment of Huntington's disease in March 2026. A Multi-Layered Pipeline Strengthens Micot Pharma's Capacity for Sustained R&D Output Beyond MT1013 and MT200605, Micot Pharma is building a broader pipeline spanning different stages of clinical development. XTL6001, a GLP-1R/GCGR/MasR triple agonist, has completed database lock for its Phase I clinical trial. By incorporating MasR into its mechanism of action, XTL6001 is designed to extend its therapeutic potential beyond weight management and metabolic regulation toward renal protection and anti-inflammatory and anti-fibrotic effects. Research relating to XTL6001 has been accepted for presentation at several major international scientific conferences, including the American Diabetes Association (ADA) Scientific Sessions 2026, the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 and ASN Kidney Week 2026. Meanwhile, MT1002 continues to advance across indications including anticoagulation during hemodialysis and acute ischemic stroke, further expanding Micot Pharma's development footprint in cardiovascular, cerebrovascular and renal diseases. Entering an Accelerated Validation Phase for R&D Outcomes Taken together, the most important takeaway from Micot Pharma's 2026 interim results is not whether a clinical-stage biotechnology company can achieve near-term profitability. Rather, three developments are taking place simultaneously. First, MT1013 has entered the critical late-stage clinical development period ahead of a potential NDA submission, while its commercialization partnership with Everest Medicines has established a clearer pathway toward commercialization. Second, the Phase II results of MT200605 have provided further clinical evidence supporting the therapeutic potential of its differentiated mechanism in acute ischemic stroke. Third, proceeds from the Company's Hong Kong listing, together with the upfront payment received under the MT1013 commercialization agreement, have substantially strengthened Micot Pharma's liquidity and capital structure, providing greater financial flexibility to advance its clinical pipeline. For investors and industry observers, these developments may represent the central theme through which Micot Pharma's first interim results following its Hong Kong listing should be understood: the Company is moving from a stage dominated by R&D investment toward one in which clinical progress, external partnerships and pipeline value are increasingly being validated through tangible milestones.
- Micot Pharma Reports Positive Operating Cash Flow and Advances Late-Stage Pipeline in 1H 2026Operating Cash Flow Turns Positive for the First Time, with a Significantly Strengthened Capital Structure On August 28, 2026, Micot Pharma (02335.HK), the first publicly listed peptide-focused innovative drug company in Hong Kong, announced its interim results for the first half of 2026. During the reporting period, the Company recorded research and development expenses of RMB128 million, representing a significant year-on-year increase of 215.9%, reflecting an acceleration in R&D investment. Meanwhile, net cash generated from operating activities reached RMB109 million, marking a turnaround from net operating cash outflow in the corresponding period of 2025. An important contributor to this shift was the commercialization partnership for MT1013. In February 2026, Micot Pharma entered into an exclusive commercialization licensing agreement with Everest Medicines for MT1013, the Company's Core Product. Under the agreement, Everest Medicines was granted exclusive commercialization rights for MT1013 in Greater China and the Asia-Pacific region excluding Japan for the treatment of secondary hyperparathyroidism (SHPT). Micot Pharma received an upfront payment of RMB200 million and is eligible to receive potential regulatory and commercial milestone payments of up to RMB1.04 billion, as well as tiered royalties based on net product sales. As of the end of June 2026, the Company's cash and financial assets totaled approximately RMB1.227 billion, compared with RMB270 million at the end of 2025. Total equity reached approximately RMB957 million, compared with net liabilities of approximately RMB960 million at the end of 2025. The Company's gearing ratio also declined substantially from 389.6% to 25.2%. For a clinical-stage biotechnology company, the strengthening of liquidity and capital structure provides important financial support for the continued advancement of multiple clinical programs. MT1013 Advances Through Phase III, with a Clearer Path Toward Commercialization Beyond its financial position, the key question for the market remains the progress and clinical potential of Micot Pharma's pipeline. MT1013 remains the Company's most advanced asset and the product closest to commercialization. MT1013 is the world’s first-in-class, new-generation dual-targeting peptide drug being developed for secondary hyperparathyroidism associated with chronic kidney disease (CKD-SHPT).The drug features a pioneering dual mechanism of action—“CaSR agonist + OGP (Osteogenic Growth Peptide) mimetic.” Unlike conventional approaches that primarily focus on suppressing parathyroid hormone (PTH), MT1013 is designed to regulate PTH, calcium and phosphorus metabolism while simultaneously activating osteogenic pathways to promote bone formation and repair. This represents a potential therapeutic shift from indirectly suppressing bone resorption toward actively promoting bone formation. The Phase III clinical study of MT1013 has completed patient enrollment, and the Company expects to submit a New Drug Application (NDA) in early 2027. In a head-to-head clinical study against the calcimimetic etelcalcetide, the composite target attainment rate for serum calcium, phosphorus, and iPTH in the MT1013 groups after 20–27 weeks of treatment was 39.29% and 34.48%, respectively, approximately 2.2–2.5 times that of etelcalcetide (15.63%). In addition, the proportion of patients in the MT1013 groups achieving a reduction of more than 30% in intact parathyroid hormone (iPTH) from baseline reached 83.9%–93.3%. Clinical data from MT1013 have also been accepted as Late-Breaking Science by the American Society of Nephrology (ASN) Kidney Week. Against this backdrop, Micot Pharma's commercialization partnership with Everest Medicines represents an important step in translating the clinical and scientific value of MT1013 into potential commercial value. Positive Phase II Data for MT200605 Further Validate Its Potential as an Innovative Stroke Therapy Shortly before the release of its interim results, Micot Pharma announced on August 26 that it had completed the Phase II clinical trial of MT200605, its internally developed candidate for the treatment of acute ischemic stroke (AIS). The study was a multicenter, randomized, double-blind, placebo-controlled Phase II trial involving 360 patients, who were randomized at a 1:1:1:1 ratio into three MT200605 dose groups and a placebo group. For the primary efficacy endpoint, the proportion of patients achieving a modified Rankin Scale (mRS) score of 0–1 in the high-dose MT200605 group was higher than that in the placebo group, with the odds ratio (OR) for functional recovery improving by more than 100% versus placebo. From a clinical-benefit perspective, the results suggest that approximately one additional patient could achieve functional independence for every six patients treated. The signal is noteworthy in the context of neuroprotection research, a field in which translating biological mechanisms into meaningful improvements in functional outcomes has historically been challenging. For the secondary endpoints, improvement in National Institutes of Health Stroke Scale (NIHSS) scores in the high-dose group began to separate from placebo by Day 7. The direction of improvement was consistent with the mRS results, with a more pronounced difference observed by Day 14, suggesting faster early neurological recovery among patients receiving high-dose MT200605. Another differentiated observation involved acute kidney injury (AKI). MT200605 demonstrated the potential to reduce the incidence of AKI among patients with AIS in a dose-dependent manner. In the high-dose group, the incidence of AKI was more than 80% lower than that in the placebo group, indicating potential renal-protective benefits in addition to its neurological effects. A Differentiated BDNF/TrkB-Based Mechanism Supporting Potential Brain and Kidney Protection Mechanistically, MT200605 is a small molecule compound that acts as a tropomyosin receptor kinase B (TrkB) agonist with brain-derived neurotrophic factor (BDNF)-like effects. By activating TrkB, it modulates downstream signaling pathways to protect the structure and function of brain neural tissues. Additionally, it enhances mitochondrial ATP synthesis and exerts antioxidant effects by scavenging oxygen free radicals. This differentiated mechanism may also contribute to the renal-protective signal observed in the Phase II trial. MT200605 has received recognition from both domestic and international scientific and regulatory communities. The program has been selected for China's National Science and Technology Major Project for Innovative Drug Development. Its preclinical and Phase I clinical findings have also been accepted for oral presentation at the 18th World Stroke Congress. In addition, the U.S. Food and Drug Administration granted Orphan Drug Designation to MT200605 for the treatment of Huntington's disease in March 2026. A Multi-Layered Pipeline Strengthens Micot Pharma's Capacity for Sustained R&D Output Beyond MT1013 and MT200605, Micot Pharma is building a broader pipeline spanning different stages of clinical development. XTL6001, a GLP-1R/GCGR/MasR triple agonist, has completed database lock for its Phase I clinical trial. By incorporating MasR into its mechanism of action, XTL6001 is designed to extend its therapeutic potential beyond weight management and metabolic regulation toward renal protection and anti-inflammatory and anti-fibrotic effects. Research relating to XTL6001 has been accepted for presentation at several major international scientific conferences, including the American Diabetes Association (ADA) Scientific Sessions 2026, the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 and ASN Kidney Week 2026. Meanwhile, MT1002 continues to advance across indications including anticoagulation during hemodialysis and acute ischemic stroke, further expanding Micot Pharma's development footprint in cardiovascular, cerebrovascular and renal diseases. Entering an Accelerated Validation Phase for R&D Outcomes Taken together, the most important takeaway from Micot Pharma's 2026 interim results is not whether a clinical-stage biotechnology company can achieve near-term profitability. Rather, three developments are taking place simultaneously. First, MT1013 has entered the critical late-stage clinical development period ahead of a potential NDA submission, while its commercialization partnership with Everest Medicines has established a clearer pathway toward commercialization. Second, the Phase II results of MT200605 have provided further clinical evidence supporting the therapeutic potential of its differentiated mechanism in acute ischemic stroke. Third, proceeds from the Company's Hong Kong listing, together with the upfront payment received under the MT1013 commercialization agreement, have substantially strengthened Micot Pharma's liquidity and capital structure, providing greater financial flexibility to advance its clinical pipeline. For investors and industry observers, these developments may represent the central theme through which Micot Pharma's first interim results following its Hong Kong listing should be understood: the Company is moving from a stage dominated by R&D investment toward one in which clinical progress, external partnerships and pipeline value are increasingly being validated through tangible milestones.
- Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentationsAlvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT80, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) prefilled syringe and autoinjector for subcutaneous administration.